plicamycin has been researched along with Carcinoma, Renal Cell in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L; Crooks, DR; Difilippantonio, S; Ferrer, M; Gibbs, BK; Guha, R; Itkin, Z; James, A; Karim, B; Klumpp-Thomas, C; Lang, M; Linehan, WM; McKnight, C; Merino, MJ; Morís, F; Ricketts, CJ; Ried, T; Schmidt, LS; Sourbier, C; Srinivasan, R; Thomas, CJ; Vocke, CD; Wangsa, D; Wei, D; Wilson, KM; Yang, Y; Zhang, X | 1 |
| Choi, KS; Jung, EM; Kim, S; Kwon, TK; Lee, JT; Lee, TJ; Park, JW | 1 |
2 other study(ies) available for plicamycin and Carcinoma, Renal Cell
| Article | Year |
|---|---|
High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma.
Topics: Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Membrane Glycoproteins; MTOR Inhibitors; Phosphatidylinositol 3-Kinase; Translocation, Genetic | 2023 |
Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Binding Sites; Breast Neoplasms; Carcinoma, Renal Cell; Caspases; Colonic Neoplasms; Down-Regulation; Female; HT29 Cells; Humans; Male; Plicamycin; Promoter Regions, Genetic; Sp1 Transcription Factor; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein | 2006 |